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OBJECTIVES We investigated whether the source of the acute phase response in unstable angina (UA) lay
within the culprit coronary plaque or distal myocardium.
BACKROUND An inflammatory response is an important component of the acute coronary syndromes.
However, its origin and mechanism remain unclear.
METHODS In 94 stable patients undergoing coronary angiography, the relationship between systemic
levels of tumor necrosis factor (TNF)-alpha, interleukin-6 (IL-6) and C-reactive protein
(CRP) and extent of atherosclerosis was studied. The temporal relationship between these
markers and troponin T (TnT) was determined in 91 patients with UA. Cytokine levels were
measured in the aortic root and coronary sinus of 36 unstable patients.
RESULTS There was no relationship found between stable coronary atherosclerosis and inflammatory
marker levels. Compared with this group, admission levels of IL-6 (3.6  0.3 ng/ml vs.
10.7  1.7 ng/ml, p  0.05) and CRP (2.3  0.1 mg/l vs. 4.6  0.6 mg/l, p  0.05) were
elevated in patients with UA. In this group, IL-6 and CRP remained elevated in those who
subsequently experienced major adverse cardiac events. This inflammatory response occurred
in parallel to the appearance of TnT. Both TNF-alpha (19.2  3.4 ng/ml vs. 17.1  3.3
ng/ml, p  0.001) and IL-6 (10.3  1.4 ng/ml vs. 7.7  1.1 ng/ml, p  0.01) were elevated
in the coronary sinus compared with aortic root in patients with UA. This was principally
observed in those who were TnT positive. There was no cytokine gradient across the culprit
plaque.
CONCLUSIONS There is an intracardiac inflammatory response in UA that appears to be the result of
low-grade myocardial necrosis. The ruptured plaque does not appear to contribute to the
acute phase response. (J Am Coll Cardiol 2002;39:1917–23) © 2002 by the American
College of Cardiology Foundation
A systemic inflammatory response often accompanies acute
coronary syndromes, and its presence has been widely
recognized as an index of further events (1). Accumulating
evidence suggests that inflammation within the atheroscle-
rotic plaque contributes to its destabilization and subsequent
disruption (2–4). The widely held view is that systemic
inflammation in unstable angina (UA) originates from
inflammatory processes within the arterial wall after plaque
disruption.
Histologic study of coronary atherectomy material has
shown considerable overlap between inflammatory infil-
trates in plaques harvested from patients with stable and
unstable angina (5). However, the systemic levels of inflam-
matory markers in patients with stable angina are somewhat
lower than those found in the acute coronary syndromes (6).
An alternative explanation to reconcile these observations
is that the focus of inflammation does not reside within the
vasculature itself but rather in injured myocardium distal to
the disrupted plaque. Thus, the precise site of, and stimulus
for, the inflammatory response that accompanies UA re-
mains unclear.
The aim of this study was to clarify these issues by
examining whether the systemic inflammatory response in
UA was due to ischemic myocardial injury and/or plaque
inflammation. We examined the relationship between stable
coronary atherosclerosis and circulating levels of inflamma-
tory markers. Secondly, in patients with UA we determined
whether a temporal relationship existed between systemic
markers of inflammation and the sensitive marker of myo-
cardial necrosis, cardiac troponin T (TnT). Finally, we
determined whether the focus of systemic inflammation in
patients with UA exists across the culprit atherosclerotic
plaque and/or the myocardium.
METHODS
Three groups of patients were prospectively studied. All had
given informed consent, and the protocol was approved by
the St. Thomas’ Hospital Local Institutional Review Board.
Group A consisted of 94 patients undergoing diagnostic
cardiac catheterization at our institution for the investiga-
tion of stable angina. Before arteriography, an arterial blood
sample was taken. Patients in this group were segregated
according to the absence or presence (defined as a diameter
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stenosis 70% on quantitative coronary angiography) of
coronary artery disease. Those with coronary artery disease
were subdivided further by the number of vessels involved.
Group B consisted of 91 patients admitted with Braun-
wald IIIb UA (7) to our own institution or to two local
general hospitals. Patients had experienced chest pain at rest
associated with electrocardiogram changes within the pre-
ceding 48 h. Exclusion criteria included myocardial infarc-
tion (MI) within six weeks, evidence of significant myocar-
dial necrosis on admission (total creatine kinase 2 times
upper limit of normal) or coexistent conditions likely to be
associated with an acute phase response. All patients re-
ceived standard medical therapy, consisting of aspirin,
subcutaneous low molecular weight heparin, intravenous
nitrates and beta-blockers, where not contraindicated. No
patients received a glycoprotein IIb/IIIa antagonist. Periph-
eral blood was sampled on admission, at 6 h, 24 h, 48 h and
7 days.
In group C there were a further 36 patients with
Braunwald IIIb UA undergoing cardiac catheterization on
clinical grounds. Before angiography the coronary sinus was
cannulated and simultaneous blood samples taken from the
coronary sinus and aortic root. In patients proceeding to
percutaneous coronary intervention, where a culprit lesion
had been identified, a Multifunctional Probing catheter
(Boston Scientific Corp., Maple Grove, Minnesota) was
passed into the distal coronary artery and blood sampled
from this site before balloon dilation.
Laboratory assays. Serum was immediately separated from
all blood samples and stored at 80°C. Levels of C-reactive
protein (CRP), interleukin (IL)-6 and tumor necrosis factor
(TNF)-alpha were determined by a solid-phase, two-site
chemiluminescent immunometric assay (Diagnostic Prod-
ucts Corp., Los Angeles, California). Cardiac troponin T
was measured using an enzyme-linked immunoassay kit
(Boehringer Mannheim, Berkshire, United Kingdom). The
results of these assays were not available to those personnel
involved in the clinical care of these patients.
Patients were classified according to the presence or
absence of a major adverse cardiac event (MACE), defined
as the 30-day need for urgent revascularization, progression
to MI or death.
Statistical analysis. The results are presented as the
mean  standard error for variables that were normally
distributed and as the median (range) where this was not the
case. Nonparametric data was normalized before statistical
analysis. The levels of CRP, IL-6 and TNF-alpha among
the patient subgroups in group A were compared with a
Kruskal-Wallis one-way analysis of variance on ranks.
Where differences were present between subgroups, this was
assessed using Dunn’s method. The same method was used
to compare these stable patients with those in the unstable
group B. The temporal relationships of CRP, IL-6, TNF-
alpha and TnT between those who subsequently experi-
enced MACE and those who did not were determined by
one-way repeated measures analysis of variance. Where a
difference was found between those who experienced
MACE and those who did not, this was tested with a
Bonferroni t test. The mean level of each marker was
determined for each patient. Linear regression analysis was
then employed in this group to determine those variables
that related to outcome and multiple linear regression to
identify those that were independently related. The rela-
tionship of aortic to coronary sinus cytokine levels was
determined with a Student t test for paired data.
RESULTS
Stable patients undergoing angiography. In patients un-
dergoing routine angiography (age 60.1  10.5, 72% men),
hypercholesterolemia was prevalent (46% of patients),
though diabetes was an uncommon finding (5%). A total of
15% of these patients had had previous coronary revascu-
larization. There was no consistent relationship found
between the presence or extent of coronary disease and the
level of inflammatory markers (Fig. 1). However, the levels
of CRP and IL-6 were both significantly lower in these
stable patients than in the patients with UA (Fig. 2).
Patients with UA. Demographics were similar between
patients who did or did not have a MACE (Table 1).
The levels of IL-6, CRP and TnT were elevated after
hospital admission among patients who experienced
MACE compared with those who did not (Fig. 3). The
systemic rise in the level of IL-6 observed among the
MACE group occurred in parallel to that of TnT and
preceded the rise in CRP by approximately 6 h. However, a
direct correlation between either CRP or IL-6 levels with
TnT was not found at any time point. By seven days after
admission, there was no longer any difference in the level of
IL-6 between these two groups (Fig. 3), whereas both CRP
and TnT remained elevated at this time in those experienc-
ing MACE (Fig. 3). No difference was found in the level of
TNF-alpha between these two groups at any time point.
Linear regression analysis showed the normalized mean
levels of CRP, IL-6 and TnT over the first 48 h after
hospital admission to be predictive of 30-day MACE.
Multiple regression analysis over this time period showed
both IL-6 (p  0.002) and TnT (p  0.002), but not CRP
(p  0.06), to be independently predictive of 30-day
MACE. Best subsets regression analysis suggested a com-
Abbreviations and Acronyms
CRP  C-reactive protein
IL  interleukin
MACE  major adverse cardiac event
MI  myocardial infarction
PTCA  percutaneous transluminal coronary angioplasty
TNF  tumor necrosis factor
TnT  troponin T
UA  unstable angina
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bination of both IL-6 and TnT to be most predictive of
subsequent MACE (Mallows Cp of 4.8, where n  5).
Coronary sinus and aortic root sampling. Among the 36
patients (age 64.8  8.1 years, 68% men) with Braunwald
IIIb UA undergoing cardiac catheterization, 35 had disease
of at least one epicardial coronary artery, and 22 (63%)
underwent urgent revascularization. These patients were
similar in their demographics to those in group B. No
difference in cytokine levels was observed between those
who did and those who did not undergo revascularization.
The levels of both TNF-alpha and IL-6 were significantly
greater in the coronary sinus compared with the aortic root
suggesting intracardiac production of these substances (Fig.
4). These patients were subdivided according to the pres-
ence or absence of an elevated TnT level at the time of
catheterization. In those with TnT elevation (n  17), the
coronary sinus levels of TNF-alpha and IL-6 were both
significantly greater than aortic levels (Fig. 4). However, a
quantitative relationship between the TnT level and the
absolute transmyocardial gradient of TNF-alpha or IL-6
Figure 1. The levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and C-reactive protein (CRP) are shown for the stable patients undergoing
angiography. No consistent relation was found between the level of these inflammatory markers and the extent of angiographic coronary disease. A 
normal coronary arteries; B  single vessel disease; C  double vessel disease; D  triple vessel disease.
Figure 2. The levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and C-reactive protein (CRP) are shown for the stable patients and the
unstable angina patients divided according to the subsequent occurrence of major adverse cardiac events (MACE). The levels of IL-6 and CRP are
substantially higher in those with unstable angina compared with those with stable symptoms (*p  0.05). A  stable patients; B  unstable patients
without MACE; C  unstable patients with MACE.
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was not found. In those without evidence of myocardial
necrosis (TnT negative), this intracardiac production of
TNF-alpha and IL-6 was no longer evident (Fig. 4). In
those proceeding directly to coronary intervention, blood
was successfully sampled distal to the culprit coronary lesion
in 11 patients. In this group, no differences were found in
the levels of TNF-alpha or IL-6 between the proximal and
distal coronary artery despite the presence of a transcardiac
cytokine gradient between the aortic root and coronary sinus
(Fig. 5).
DISCUSSION
This study supports the premise that the myocardium is the
principal site for the systemic elevation in inflammatory
markers found in UA. Furthermore, early activation of the
inflammatory response in these unstable patients was asso-
ciated with an adverse outcome.
Relationship between inflammatory markers and coro-
nary disease. Among patients with stable angina, no rela-
tionship existed between the levels of TNF-alpha, IL-6 or
CRP and the extent of coronary artery disease. It has
previously been observed that clinically silent plaque rupture
is common (8). Furthermore, fractured fibrous caps with
intense inflammation are a common finding in the abdom-
inal aorta at necropsy, and asymptomatic carotid plaque
rupture may be found in almost one-fifth of elderly persons
at autopsy (9). Based on these observations, it might be
expected that those with a heavy burden of coronary disease
would have demonstrably higher inflammatory markers
than those without. The absence of a relationship between
the number of diseased vessels (as a surrogate measure of
stable plaque burden) and systemic inflammatory response
implies that there is a process in addition to plaque rupture
ongoing among those with UA.
Inflammatory markers in unstable patients. In this un-
stable group, plaque disruption was the presumed underly-
ing etiology in all patients. A systemic inflammatory re-
sponse was present in 40% of these patients, and this was
associated with subsequent MACE. Among these patients,
both IL-6 and TnT were elevated at the time of hospital
admission with further elevations in the levels of these two
proteins occurring in parallel over the subsequent 48 h. This
suggests that myocardial necrosis and systemic inflamma-
tory activity are closely related in this group. If plaque
disruption was the sole mediator of the inflammatory
response, then it would have been difficult to explain the
dichotomy that exists between these two groups of patients.
Transcardiac cytokine gradient. The rise in the level of
both IL-6 and TNF-alpha between the aortic root and
coronary sinus in patients with UA suggests intracardiac
synthesis of these substances. Importantly, when the pa-
tients are divided according to their troponin T status, this
intracardiac inflammatory response appears to be present
principally in those with evidence of myocardial injury.
Microscopic multifocal MI associated with embolized plate-
let microthrombi has been well described in UA (10) and is
believed to be the mechanism for the elevation in troponin
T found in these patients (11). As no gradient in cytokine
concentrations could be demonstrated between the aorta
and the vessel distal to the culprit lesion in patients with
UA, the inflammatory response we measured appears to lie
within the “downstream” myocardium. The relationship
between intracardiac cytokine synthesis and troponin T
elevation further suggests that the inflammatory response is
related to necrosis within the myocardium.
Interestingly, the systemic levels of TNF-alpha were
similar in all groups. Though TNF-alpha is one of the
determinates of IL-6 synthesis, it is also modulated by IL-1.
Interleukin-1 receptor antagonist has been found previously
to be elevated in UA (12) and may account for the systemic
increases in IL-6 that have been observed here.
IL-6 and prognosis. These data suggest a prognostic role
for IL-6 in the early risk stratification of patients with UA.
In those who had a subsequent MACE, both IL-6 and TnT
were elevated at hospital admission with CRP becoming
elevated some hours later. Elevation of TnT in UA is
increasingly seen as having important prognostic implica-
tions (13). These results suggest that elevation of IL-6 may
carry similar prognostic connotations. During the first 48 h
after admission, the levels of IL-6, CRP and TnT remained
elevated in those who subsequently had a MACE and may
permit discrimination of these patients over this time
period. One week after admission, the prognostic value of
IL-6 had been lost, though both CRP and TnT remained
elevated in those who experienced a MACE. We were,
however, unable to demonstrate a distinct correlation be-
tween the levels of these inflammatory markers and TnT at
these time points. Though the systemic half-life of CRP is
longer than IL-6, they are both somewhat shorter than
TnT, which may, in part, explain this observation.
A role for immunosuppression? An inflammatory re-
sponse has previously been observed among patients with
acute MI and found to be related to infarct size and
Table 1. The Demographics of the Unstable Patients Divided
According to the Subsequent Occurrence of MACE
MACE No MACE
(n  37) (n  54)
Age (mean  SD), yrs 65.9  11.2 67.8  8.3
Gender (M/F) 23/14 36/18
Hypertension 9 (24%) 15 (28%)
Diabetes 3 (8%) 2 (6%)
Smoking 5 (19%) 6 (11%)
Family history of IHD 14 (38%) 18 (33%)
Previous stable angina 8 (22%) 19 (35%)
Previous episode of unstable angina 9 (24%) 15 (28%)
Previous history of MI 6 (16%) 8 (15%)
Peripheral vascular disease 2 (5%) 2 (4%)
Cerebrovascular disease 2 (5%) 0 (0%)
Previous PTCA 1 (3%) 3 (6%)
Previous CABG 3 (8%) 5 (9%)
CABG  coronary artery bypass graft; IHD  ischemic heart disease; MACE 
major adverse cardiac event; MI  myocardial infarction; PTCA  percutaneous
transluminal coronary angioplasty.
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prognosis (14–16). In light of this observation, the effect of
immunosuppression with methylprednisolone after MI was
tested and found to be deleterious (17). A possible beneficial
role for immunosuppresion in UA has been suggested.
However, as the systemic inflammatory response appears to
reflect low level myocardial necrosis, it is interesting that
immunosuppression in this setting resulted in similar ad-
verse outcomes to those seen in the previous infarct studies,
as recently shown in the Methylprednisolone in Unstable
Angina (MUNA) trial (18).
Clinical implications. It has previously been shown that,
in patients with UA undergoing coronary intervention, the
IL-6 level in those with a normal baseline level does not
change after percutaneous transluminal coronary angio-
plasty (PTCA) (19). However, in those with an already
elevated IL-6, there is often a further significant rise after
PTCA (19). Percutaneous transluminal coronary angio-
plasty among patients with UA is known to be associated
with distal embolization within the coronary artery of
platelet microthrombi and a significant risk of periproce-
dural MI (20,21). Although speculative, if elevation of IL-6
is due to myocardial microinfarction from previous platelet
aggregate embolization, this may predispose to further
embolization at the time of PTCA with a further rise in
IL-6. Those with a normal IL-6 level before their procedure
are unlikely to have had significant recent embolization,
implying relative absence of thrombus within the coronary
artery.
The glycoprotein IIb/IIIa inhibitors reduce the risk of
periprocedural MI in patients with UA undergoing PTCA
(20), particularly in those with elevated TnT (22). Further-
more, abciximab has recently been shown to reduce the
inflammatory response among these patients (23). Incorpo-
rating data on inflammatory status may allow improved
targeting of those patients at risk of periprocedural adverse
events for early antiplatelet therapy.
Study limitations. Measurement of coronary blood flow
would allow the amount of IL-6 and TNF-alpha produced
Figure 3. The levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, C-reactive protein (CRP) and troponin T are shown for the patients with
unstable angina for the first seven days after admission. The systemic inflammatory response exhibited in the patients who subsequently experienced major
adverse cardiac events (MACE) occurs in parallel to a rise in troponin T. Open circle  patients who experienced MACE; solid box  patients who did
not experience MACE.
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within the heart to be accurately determined. However, this
would require further manipulation at the time of catheter-
ization among patients who are unstable, which may be
problematic. We have postulated that the source of cytokine
production lies within the myocardium and occurs in
response to microinfarction. However, further sampling of
blood in the distal coronary artery and selective cannulation
of the cardiac veins would help to establish this further. In
addition, larger studies are needed to determine the effec-
tiveness of these markers in risk stratification and also to test
their role in patients undergoing coronary intervention.
CONCLUSIONS
Adverse events in UA are associated with early elevation of
IL-6 and troponin T. The systemic appearance of IL-6
occurs in parallel to that of troponin T among those having
a subsequent MACE. Both TNF-alpha and IL-6 are
actively generated within the heart among these patients,
and this inflammatory response is found principally in those
with evidence of myocardial necrosis. This suggests that the
systemic inflammatory response may be the result of the
myocardial microinfarction known to occur in this group.
The admission levels of IL-6 appear to be an independent
predictor of MACE in UA and, in combination with
troponin T, may allow improved risk stratification of these
patients. Further studies are warranted, as an improved
understanding of this inflammatory process may lead to
novel therapeutic approaches and better application of
currently available therapies.
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